Radioimmunotherapy of interleukin-2Rα-expressing adult T-cell leukemia with Yttrium-90-labeled anti-Tac

T. A. Waldmann, J. D. White, J. A. Carrasquillo, J. C. Reynolds, C. H. Paik, O. A. Gansow, M. W. Brechbiel, E. S. Jaffe, T. A. Fleisher, C. K. Goldman, L. E. Top, R. Bamford, S. Zaknoen, E. Roessler, Claude Sportes, R. England, H. Litou, J. A. Johnson, T. Jackson-White

Research output: Contribution to journalArticle

206 Citations (Scopus)

Abstract

Adult T-cell leukemia (ATL) is a malignancy of mature lymphocytes caused by the retrovirus human T-cell lymphotropic virus-I. It is an aggressive leukemia with a median survival time of 9 months; no chemotherapy regimen appears successful in inducing long-term disease-free survival. The scientific basis of the present study is that ATL cells express high-affinity interleukin-2 receptors identified by the anti-Tac monoclonal antibody, whereas normal resting cells do not. To exploit this difference, we administered anti-Tac armed with Yttrium-90 ( 90 Y) to 18 patients with ATL initially (first 9 patients) in a phase I doso-escalation trial and subsequently (second group of 9 patients) in a phase II trial involving a uniform 10-mCi dose of 90 Y-labeled anti-Tac. Patients undergoing a remission were permitted to receive up to eight additional doses. At the 5- to 15-mCi doses used, 9 of 16 evaluable patients responded to 90 Y anti-Tac with a partial (7 patients) or complete (2 patients) remission. The responses observed represent improved efficacy in terms of length of remission when compared with previous results with unmodified anti-Tac. Clinically meaningful (≥grade 3) toxicity was largely limited to the hematopoietic system. In conclusion, radioimmunotherapy with 9 0Y anti-Tac directed toward the IL-2R expressed on ATL cells may provide a useful approach for treatment of this aggressive malignancy.

Original languageEnglish (US)
Pages (from-to)4063-4075
Number of pages13
JournalBlood
Volume86
Issue number11
StatePublished - Jan 1 1995

Fingerprint

Radioimmunotherapy
Yttrium
Adult T Cell Leukemia Lymphoma
T-cells
Interleukins
Chemotherapy
Lymphocytes
Interleukin-2 Receptors
Viruses
Hematopoietic System
Toxicity
Retroviridae
Monoclonal Antibodies
Disease-Free Survival
Neoplasms
Leukemia
T-Lymphocytes
Drug Therapy
Survival

ASJC Scopus subject areas

  • Biochemistry
  • Immunology
  • Hematology
  • Cell Biology

Cite this

Waldmann, T. A., White, J. D., Carrasquillo, J. A., Reynolds, J. C., Paik, C. H., Gansow, O. A., ... Jackson-White, T. (1995). Radioimmunotherapy of interleukin-2Rα-expressing adult T-cell leukemia with Yttrium-90-labeled anti-Tac. Blood, 86(11), 4063-4075.

Radioimmunotherapy of interleukin-2Rα-expressing adult T-cell leukemia with Yttrium-90-labeled anti-Tac. / Waldmann, T. A.; White, J. D.; Carrasquillo, J. A.; Reynolds, J. C.; Paik, C. H.; Gansow, O. A.; Brechbiel, M. W.; Jaffe, E. S.; Fleisher, T. A.; Goldman, C. K.; Top, L. E.; Bamford, R.; Zaknoen, S.; Roessler, E.; Sportes, Claude; England, R.; Litou, H.; Johnson, J. A.; Jackson-White, T.

In: Blood, Vol. 86, No. 11, 01.01.1995, p. 4063-4075.

Research output: Contribution to journalArticle

Waldmann, TA, White, JD, Carrasquillo, JA, Reynolds, JC, Paik, CH, Gansow, OA, Brechbiel, MW, Jaffe, ES, Fleisher, TA, Goldman, CK, Top, LE, Bamford, R, Zaknoen, S, Roessler, E, Sportes, C, England, R, Litou, H, Johnson, JA & Jackson-White, T 1995, 'Radioimmunotherapy of interleukin-2Rα-expressing adult T-cell leukemia with Yttrium-90-labeled anti-Tac', Blood, vol. 86, no. 11, pp. 4063-4075.
Waldmann TA, White JD, Carrasquillo JA, Reynolds JC, Paik CH, Gansow OA et al. Radioimmunotherapy of interleukin-2Rα-expressing adult T-cell leukemia with Yttrium-90-labeled anti-Tac. Blood. 1995 Jan 1;86(11):4063-4075.
Waldmann, T. A. ; White, J. D. ; Carrasquillo, J. A. ; Reynolds, J. C. ; Paik, C. H. ; Gansow, O. A. ; Brechbiel, M. W. ; Jaffe, E. S. ; Fleisher, T. A. ; Goldman, C. K. ; Top, L. E. ; Bamford, R. ; Zaknoen, S. ; Roessler, E. ; Sportes, Claude ; England, R. ; Litou, H. ; Johnson, J. A. ; Jackson-White, T. / Radioimmunotherapy of interleukin-2Rα-expressing adult T-cell leukemia with Yttrium-90-labeled anti-Tac. In: Blood. 1995 ; Vol. 86, No. 11. pp. 4063-4075.
@article{2e7192d794894f7d81b65fb5e27af5a8,
title = "Radioimmunotherapy of interleukin-2Rα-expressing adult T-cell leukemia with Yttrium-90-labeled anti-Tac",
abstract = "Adult T-cell leukemia (ATL) is a malignancy of mature lymphocytes caused by the retrovirus human T-cell lymphotropic virus-I. It is an aggressive leukemia with a median survival time of 9 months; no chemotherapy regimen appears successful in inducing long-term disease-free survival. The scientific basis of the present study is that ATL cells express high-affinity interleukin-2 receptors identified by the anti-Tac monoclonal antibody, whereas normal resting cells do not. To exploit this difference, we administered anti-Tac armed with Yttrium-90 ( 90 Y) to 18 patients with ATL initially (first 9 patients) in a phase I doso-escalation trial and subsequently (second group of 9 patients) in a phase II trial involving a uniform 10-mCi dose of 90 Y-labeled anti-Tac. Patients undergoing a remission were permitted to receive up to eight additional doses. At the 5- to 15-mCi doses used, 9 of 16 evaluable patients responded to 90 Y anti-Tac with a partial (7 patients) or complete (2 patients) remission. The responses observed represent improved efficacy in terms of length of remission when compared with previous results with unmodified anti-Tac. Clinically meaningful (≥grade 3) toxicity was largely limited to the hematopoietic system. In conclusion, radioimmunotherapy with 9 0Y anti-Tac directed toward the IL-2R expressed on ATL cells may provide a useful approach for treatment of this aggressive malignancy.",
author = "Waldmann, {T. A.} and White, {J. D.} and Carrasquillo, {J. A.} and Reynolds, {J. C.} and Paik, {C. H.} and Gansow, {O. A.} and Brechbiel, {M. W.} and Jaffe, {E. S.} and Fleisher, {T. A.} and Goldman, {C. K.} and Top, {L. E.} and R. Bamford and S. Zaknoen and E. Roessler and Claude Sportes and R. England and H. Litou and Johnson, {J. A.} and T. Jackson-White",
year = "1995",
month = "1",
day = "1",
language = "English (US)",
volume = "86",
pages = "4063--4075",
journal = "Blood",
issn = "0006-4971",
publisher = "American Society of Hematology",
number = "11",

}

TY - JOUR

T1 - Radioimmunotherapy of interleukin-2Rα-expressing adult T-cell leukemia with Yttrium-90-labeled anti-Tac

AU - Waldmann, T. A.

AU - White, J. D.

AU - Carrasquillo, J. A.

AU - Reynolds, J. C.

AU - Paik, C. H.

AU - Gansow, O. A.

AU - Brechbiel, M. W.

AU - Jaffe, E. S.

AU - Fleisher, T. A.

AU - Goldman, C. K.

AU - Top, L. E.

AU - Bamford, R.

AU - Zaknoen, S.

AU - Roessler, E.

AU - Sportes, Claude

AU - England, R.

AU - Litou, H.

AU - Johnson, J. A.

AU - Jackson-White, T.

PY - 1995/1/1

Y1 - 1995/1/1

N2 - Adult T-cell leukemia (ATL) is a malignancy of mature lymphocytes caused by the retrovirus human T-cell lymphotropic virus-I. It is an aggressive leukemia with a median survival time of 9 months; no chemotherapy regimen appears successful in inducing long-term disease-free survival. The scientific basis of the present study is that ATL cells express high-affinity interleukin-2 receptors identified by the anti-Tac monoclonal antibody, whereas normal resting cells do not. To exploit this difference, we administered anti-Tac armed with Yttrium-90 ( 90 Y) to 18 patients with ATL initially (first 9 patients) in a phase I doso-escalation trial and subsequently (second group of 9 patients) in a phase II trial involving a uniform 10-mCi dose of 90 Y-labeled anti-Tac. Patients undergoing a remission were permitted to receive up to eight additional doses. At the 5- to 15-mCi doses used, 9 of 16 evaluable patients responded to 90 Y anti-Tac with a partial (7 patients) or complete (2 patients) remission. The responses observed represent improved efficacy in terms of length of remission when compared with previous results with unmodified anti-Tac. Clinically meaningful (≥grade 3) toxicity was largely limited to the hematopoietic system. In conclusion, radioimmunotherapy with 9 0Y anti-Tac directed toward the IL-2R expressed on ATL cells may provide a useful approach for treatment of this aggressive malignancy.

AB - Adult T-cell leukemia (ATL) is a malignancy of mature lymphocytes caused by the retrovirus human T-cell lymphotropic virus-I. It is an aggressive leukemia with a median survival time of 9 months; no chemotherapy regimen appears successful in inducing long-term disease-free survival. The scientific basis of the present study is that ATL cells express high-affinity interleukin-2 receptors identified by the anti-Tac monoclonal antibody, whereas normal resting cells do not. To exploit this difference, we administered anti-Tac armed with Yttrium-90 ( 90 Y) to 18 patients with ATL initially (first 9 patients) in a phase I doso-escalation trial and subsequently (second group of 9 patients) in a phase II trial involving a uniform 10-mCi dose of 90 Y-labeled anti-Tac. Patients undergoing a remission were permitted to receive up to eight additional doses. At the 5- to 15-mCi doses used, 9 of 16 evaluable patients responded to 90 Y anti-Tac with a partial (7 patients) or complete (2 patients) remission. The responses observed represent improved efficacy in terms of length of remission when compared with previous results with unmodified anti-Tac. Clinically meaningful (≥grade 3) toxicity was largely limited to the hematopoietic system. In conclusion, radioimmunotherapy with 9 0Y anti-Tac directed toward the IL-2R expressed on ATL cells may provide a useful approach for treatment of this aggressive malignancy.

UR - http://www.scopus.com/inward/record.url?scp=0028840870&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0028840870&partnerID=8YFLogxK

M3 - Article

VL - 86

SP - 4063

EP - 4075

JO - Blood

JF - Blood

SN - 0006-4971

IS - 11

ER -